process
how is it made?
Our process combines growth factor and other constituents of platelet-rich plasma, a proprietary hyaluronic acid or chitosan, and other ingredients into various formulations and material states. These products are pathogen inactivated using multiple technologies and all plasma is collected from FDA-licensed blood center partners.
learn more about:
our platform
Our platform leverages growth factors derived from donated human platelet-rich plasma and proprietary hyaluronic acid (HA) or chitosan. The tissue-repairing benefits of plasma-derived products, combined with the sustained action and impact of HA or chitosan, may provide relief and long-lasting therapeutic action.
our products
Our therapeutic formulation is suitable for a variety of products, including liquid eye drops, gels, ointments, contact lenses, contoured bandages, and wound dressings. Initially, ECI is pursuing ophthalmic indications for neurotrophic keratopathy (NK) and dry eye disease (DED).
ECI’s pipeline includes indications for ophthalmic burns, epithelial defects, endothelial diseases, limb stem cell deficiency, ocular graft-versus-host disease (GvHD), corneal abrasions, and chronic wounds.
product safety
The safety of our products is paramount. To ensure that our products are as safe as possible, pathogen inactivation and removal technologies like the INTERCEPT Blood System for Plasma and nanofiltration have been incorporated into our manufacturing process.
ECI has met with the FDA and aligned on an orthogonal (multi-step) safety plan meeting all regulatory requirements.